Target aging biology.
Transform age-related diseases.
Nebula Longevity is an emerging gerotherapeutics venture developing small-molecule programs that target cellular senescence, neuroinflammation, tissue remodeling, and functional decline.
Built around diseases where aging biology matters
A focused geroscience strategy starts with measurable disease biology and functional endpoints, then expands as data and intellectual property mature.
Cognitive resilience
Targeting senescence-associated neuroinflammation and loss of neural tissue resilience as a druggable driver of age-related cognitive decline.
Cancer persistence
Addressing therapy-induced senescent-like tumor states linked to relapse, resistance, and inflammatory remodeling.
Fibrosis, inflammation & tissue aging
Building programs around chronic inflammatory and tissue-remodeling mechanisms shared across aging diseases.
Natural-product inspired. Drug-development disciplined.
The platform uses phenotypic discovery, mechanism validation, and computational prioritization to advance candidate programs without publicly disclosing proprietary compound identities.
Why gerotherapeutics?
Many chronic diseases of aging share biological mechanisms. Targeting those mechanisms may create broader therapeutic value than treating every downstream disease in isolation.
Why now?
Modern aging biology, high-content phenotyping, and translational disease models make it possible to build drug programs around functional healthspan endpoints.